Pfizer Global Medical Grants (GMG) – 2022/2023 Global Cachexia ASPIRE – RFP

Well-being, Health and Biomedical Discovery

Deadlines

Academic Unit: inquire with unit

Memorial Deadline: Tuesday 20th, December 2022

External Deadline: Thursday 5th, January 2023


Description

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Date RFP Issued: September 20, 2022
Geographic Scope: Global
Clinical Area: Cachexia
Link to full RFP: 2022/2023 Global Cachexia ASPIRE
Application Due Date: January 5, 2023

Specific Area of Interest: The intent of this RFP is to support research projects in the following categories:

  • – Evidence generation in Understanding Cachexia/Unintentional Weight Loss in Cancer or Heart Failure
  • – Role of GDF-15/GFRAL Pathway in Disease
  • – GDF-15/GFRAL Biology
    – Natural History (longitudinal) studies specifically related to cachexia/weight loss and/or heart failure
  • Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Jessica Romano, Grant Officer (jessica.romano@pfizer.com).

Funding Sources

Pfizer Inc



This opportunity was posted by: RGCS

Last modified: September 20, 2022